What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
During the last three months, 11 analysts shared their evaluations of Alpine Immune Sciences (NASDAQ:ALPN), revealing diverse outlooks…
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success – This Time Focused On Pain Management Drugs
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers.
Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What’s Driving Markets Thursday?
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures within the basket.
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Rallybio (NASDAQ:RLYB) shares moved upwards by 70.5% to $2.78 during Thursday’s regular session. The company’s market cap…
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
Vertex Pharmaceutical’s Move Beyond Its $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to close Q2 2024. VRTX expanding into kidney disease treatment.
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Eliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday’s pre-market session. The market value…
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As ‘Phenomenal Buying Opportunity’
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons